» Authors » Paul L Bollyky

Paul L Bollyky

Explore the profile of Paul L Bollyky including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 119
Citations 3301
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim M, Suh G, Cullen G, Perez Rodriguez S, Dharmaraj T, Chang T, et al.
J Clin Invest . 2025 Mar; 135(5). PMID: 40026251
Bacteriophage (phage) therapy has emerged as a promising solution to combat the growing crisis of multidrug-resistant (MDR) infections. There are several international centers actively engaged in implementation of phage therapy,...
2.
Echterhof A, Dharmaraj T, Blankenberg P, Hajfathalian M, Blankenberg F, Sacher J, et al.
bioRxiv . 2025 Feb; PMID: 39975350
Bacteriophages, viruses that selectively infect bacteria, are increasingly explored as potential therapies to combat antibiotic-resistant infections. Effective phage purification is vital for therapeutic use, particularly to reduce endotoxin (lipopolysaccharide, LPS)...
3.
Echterhof A, Dharmaraj T, Blankenberg P, Targ B, Bollyky P, Smith N, et al.
bioRxiv . 2025 Feb; PMID: 39975270
In 2019 there were over 2.8 million cases of antibiotic-resistant bacterial infection in the US with gram negative organisms having up to a 6% rate of mortality. Bacteriophage (phage) therapy...
4.
Chang T, Pourtois J, Haddock N, Furukawa D, Kelly K, Amanatullah D, et al.
mSphere . 2025 Feb; :e0090424. PMID: 39945525
Lysogenic bacteriophages can integrate their genome into the bacterial chromosome in the form of a prophage and can promote genetic transfer between bacterial strains . However, the contribution of lysogenic...
5.
Pourtois J, Haddock N, Gupta A, Khosravi A, Martinez H, Schmidt A, et al.
bioRxiv . 2025 Jan; PMID: 39868244
Pf bacteriophages, lysogenic viruses that infect , are implicated in the pathogenesis of chronic infections; phage-infected (Pf+) strains are known to predominate in people with cystic fibrosis (pwCF) who are...
6.
Kim M, Chen Q, Echterhof A, Pennetzdorfer N, McBride R, Banaei N, et al.
Nat Commun . 2024 Nov; 15(1):9987. PMID: 39609398
Bacteriophage (phage) therapy is a promising therapeutic modality for multidrug-resistant bacterial infections, but its application is mainly limited to personalized therapy due to the narrow host range of individual phages....
7.
Burgener E, Gupta A, Nakano K, Gibbs S, Sommers M, Khosravi A, et al.
J Cyst Fibros . 2024 Nov; PMID: 39490215
Background: The Pseudomonas filamentous bacteriophage (Pf) infects Pseudomonas aeruginosa (Pa) and is abundant in the airways of many people with cystic fibrosis (CF) (pwCF). We previously demonstrated that Pf promotes...
8.
Nagy N, Czepiel K, Kaber G, Stefanovski D, Hargil A, Pennetzdorfer N, et al.
Cells . 2024 Oct; 13(20. PMID: 39451245
Given that the extracellular matrix polymer hyaluronan (HA) has been implicated in longevity, we asked whether 4-methylumbelliferone (4-MU), an inhibitor of HA synthesis, impacts lifespan in mice. We designed a...
9.
Echterhof A, Dharmaraj T, Khosravi A, McBride R, Miesel L, Chia J, et al.
JCI Insight . 2024 Oct; 9(20). PMID: 39435664
With the increasing prevalence of antimicrobial-resistant bacterial infections, there is interest in using bacteriophages (phages) to treat such infections. However, the factors that govern bacteriophage pharmacokinetics in vivo remain poorly...
10.
Cullen G, Salazar K, Terwilliger A, Aslam S, Clark J, Maresso A, et al.
Phage (New Rochelle) . 2024 Oct; 5(3):120-125. PMID: 39372359
Multidrug resistant infections are a challenge in the health care setting and a cause of patient morbidity and mortality. Bacteriophages (phages) are viruses that target and kill bacteria and have...